

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/441,140
				Filing Date	November 16, 1999
				First Named Inventor	Beka SOLOMON
				Group Art Unit	1647
				Examiner Name	C. Nichols
				Attorney Docket Number	SOLOMON=1R
Sheet	1	of	1		

Examiner Initials*	Cite No.¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code² (if known)			
CSO	FU	US 00/201,430	11/30/1998	Schenk	
		US 09/497,553	02/03/2000	Schenk	
		US 08/724,477	11/28/2000	Schenk	
		US 00/720,027	11/28/2000	Schenk	
		US 00/724,702	11/28/2000	Schenk	
		US 09/734,408	11/28/2000	Schenk	
		US 00/734,430	11/28/2000	Schenk	
	FV	US 08/925,580	05/28/1999	Schenk	
		US 00/730,743	11/27/2000	Schenk	
		US 00/733,760	11/27/2000	Schenk	
		US 00/734,310	11/27/2000	Schenk	
		US 09/720,304	11/27/2000	Schenk	
		US 00/734,195	11/27/2000	Schenk	
		US 08/920,815	05/26/2000	Schenk	
		US 09/721,040	11/28/2000	Schenk	
	US 00/734,061	11/28/2000	Schenk		
FX		US 00/680,018	05/28/2000	Schenk et al.	
		US 09/724,562	11/28/2000	Schenk et al.	
		US 00/732,544	11/28/2000	Schenk et al.	
		US 00/734,273	11/28/2000	Schenk et al.	
		US 00/734,551	11/28/2000	Schenk et al.	
		US 09/724,285	11/28/2000	Schenk et al.	
FY		US 09/500,013	05/28/00	Schenk et al.	
		US 09/720,760	11/28/2000	Schenk et al.	
		US 09/724,291	11/28/2000	Schenk et al.	
CFO		US 00/070,704	03/13/2001	Schenk	

CONSIDERED; DO NOT PRINT.

[illegible]

Examiner Signature	<i>L. Milled</i>	Date Considered	5/6/04
-----------------------	------------------	--------------------	--------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov of MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	4542 1647
Examiner Name	G. Bessel NICHOLS
Attorney Docket Number	SOLOMON=1R

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
CSO	AE	5,750,349	A	Suzuki et al	05-12-1998	
	AF	5,753,624	A	McMichael et al	05-19-1998	
	AG	5,851,996	A	Kline	12-22-1998	
CSO	AH	5,955,317	A	Suzuki et al	09-21-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
CSO	AI	WO	95/31996	A1	MILKHAUS LABORATORY	11-30-1995

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)	
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)	
	AL	JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)	
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)	
	AN	MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)	
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)	
	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)	
CSO	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", May 2002 (www.elan.com/NewsRoom)	

Examiner
Signature


G. M. Nichols

Date
Considered

7/30/02 TECH CENTER 1600/2900

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642-1647
Examiner Name	S. Unger MICHOUS
Attorney Docket Number	SOLOMON=1R


U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
ES	AR	6,417,178	B1	Klunk et al	07-09-2002	
	AS	6,284,221	B1	Schenk et al	09-04-2001	
	AT	6,262,335	B1	Hsiao et al	07-17-2001	
	AU	6,114,133	-	Seubert et al	09-05-2000	
	AV	5,958,883	-	Snow	09-28-1999	
	AW	5,955,079	-	Mond et al	09-21-1999	
	AX	5,877,399	-	Hsiao et al	03-02-1999	
	AY	5,869,093	-	Weiner et al	02-09-1999	
	AZ	5,869,054	-	Weiner et al	02-09-1999	
	BA	5,849,298	-	Weiner et al	12-15-1998	
	BB	5,837,473	-	Maggio et al	11-17-1998	
	BC	5,780,587	-	Potter	07-14-1998	
	BD	5,744,368	-	Goldgaber et al	04-28-1998	
	BE	5,736,142	-	Sette et al	04-07-1998	
	BF	5,733,547	-	Weiner et al	03-31-1998	
	BG	5,679,348	-	Nesburn et al	10-21-1997	
	BH	5,645,820	-	Hafler et al	07-08-1997	
	BI	5,641,474	-	Hafler et al	06-24-1997	
	BJ	5,641,473	-	Hafler et al	06-24-1997	
	BK	5,612,486	-	McConlogue et al	03-18-1997	
	BL	5,605,811	-	Seubert et al	02-25-1997	
	BM	5,585,100	-	Mond et al	12-17-1997	
	BN	5,571,500	-	Hafler et al	11-05-1996	
	BO	5,571,499	-	Hafler et al	11-05-1996	
	BP	5,441,870	-	Seubert et al	08-15-1995	
	BQ	5,434,170	-	Andrulis, Jr.	07-18-1995	
	BR	5,387,742	-	Cordell	02-07-1995	
	BS	5,270,165	-	Van Nostrand et al	12-14-1993	
	BT	5,231,170	-	Averback	07-27-1993	
	BU	5,231,000	-	Majocha et al	07-27-1993	
	BV	5,220,013	-	Ponte et al	06-15-1993	
	BW	5,208,036	-	Eppstein et al	05-04-1993	
	BX	5,192,753	-	McGeer et al	03-09-1993	
	BY	5,187,153	-	Cordell et al	03-09-1993	
	BZ	5,057,540	-	Kensil et al	10-15-1991	
	CA	5,004,697	-	Pardridge	04-20-1991	
ES	CB	4,666,829	-	Glenner et al	05-19-1987	

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1842 1647
Examiner Name	S. Unger NICHOLS
Attorney Docket Number	SOLOMON=1R

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number	Kind Code ⁵ (if known)				
ES	CC	WO	94/28412	A1	The Miriam Hospital	12-08-1994		
	CD	WO	94/03615	A1	Medeva Holdings B.V.	02-17-1994		
	CE	WO	94/01772	A1	Children's Med. Cen. Corp.	01-20-1994		
	CF	EP	0 276 723	B1	Bayer AG	12-08-1993		Yes
	CG	WO	93/21950	A1	Medeva Holdings B.V.	11-11-1993		
	CH	WO	93/16724	A1	Autoimmune, Inc.	09-02-1993		
	CI	WO	93/15760	A1	Mond et al	08-19-1993		
	CJ	WO	93/14200	A1	TSI Corporation	07-22-1993		
	CK	WO	93/04194	A1	Regents of U. of Minn.	03-04-1993		
	CL	WO	93/02189	A1	Regents of U. of Cal.	02-04-1993		
	CM	WO	92/13069	A1	Imp. Col. of Sci. Tech. & Med.	08-06-1992		
	CN	WO	92/06708	A1	Brigham and Women's Hosp.	04-30-1992		
	CO	WO	92/06187	A1	The Upjohn Company	04-16-1992		
	CP	WO	91/19810	A1	California Biotechnology Inc.	12-26-1991		
	CQ	WO	91/16819	A1	Molecular Rx, Inc.	11-14-1991		
	CR	EP	0 451 700	A1	Miles Inc.	10-16-1991		
	CS	WO	91/12816	A1	Autoimmune, Inc.	09-05-1991		
	CT	WO	91/08760	A1	Brigham and Women's Hosp.	06-27-1991		
	CU	WO	90/12871	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
	CV	WO	90/12870	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
	CW	GB	2 220 211	A	Ribi Immunochem Research Inc.	01-04-1990		
	CX	WO	89/06689	A1	McLean Hosp. Corp. & U. Roch.	07-27-1989		
	CY	WO	89/05242	A1	McLean Hosp. Corp. & U. Roch.	07-13-1989		
	CZ	WO	89/03687	A1	Genetics Institute, Inc.	05-05-1989		
	DA	WO	89/01343	A1	Regents of U. of Cal.	02-23-1989		
ES	DB	WO	88/10120	A1	Brigham and Women's Hosp.	12-29-1988		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
ES	DC	BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J Mol Biol 225(4):1075-1093 (1992)	

Examiner
SignatureDate
Considered

9/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/57 (10/96)



PTO/SB/57 (10/96)

RECEIVED

NOV 15 2002

TECH CENTER 1600

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642-1647
Examiner Name	S. Ungar
Attorney Docket Number	SOLOMON=1R


DR	GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990)
DS	GASKIN et al, "Human antibodies reactive with β -amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993)
DT	GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 120(3):885-890 (1984)
DU	GLENNER et al, "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984)
DV	GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> 349:704-706 (1991)
DW	GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949)
DX	HAASS et al "Amyloid β -peptide is produced by cultured cells during normal metabolism," <u>Nature</u> 359(6393):322-5 (1992)
DY	HAGA et al, "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993)
DZ	HARRINGTON et al, "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993)
EA	HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2", <u>Immunology</u> 78:643-649 (1993)
EB	HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991)
EC	HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J Neuroimmunol</u> 52(2):147-152 (1994)
ED	IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987)
EE	ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989)

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/57 (10/96)

TECH CENTER

RECEIVED

Substitute for form 1449/APTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5

of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1042-1647
Examiner Name	S. Ungar
Attorney Docket Number	SOLOMON=1R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	EF	WATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> 13:45-53 (1994)	
	EG	JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immunol Rev</u> 62:185-216 (1982)	
	EH	JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am J Pathol</u> 138(2):373-384 (1991)	
	EI	KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res Immunol</u> 143:637-641 (1992)	
	EJ	KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C- terminal fragment of human amyloid precursor protein," <u>Nature</u> 354:476-478 (1991)	
	EK	LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993)	
	EL	LANGER, "New Methods of Drug Delivery," <u>Science</u> 249:1527-1532 (1990)	
	EM	LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993)	
	EN	LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991)	
	EO	MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nuc Med</u> 33:2184-2189 (1992)	
	EP	MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994)	
CSO	EQ	MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985)	

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/57 (10/96)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6

of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642-1047
Examiner Name	S. Ungar
Attorney Docket Number	SOLOMON=1R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	ER	McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," <u>J Neurosci Res</u> 31:428-442 (1992)	
	ES	MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J Exp Med</u> 174:791-798 (1991)	
	ET	MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J Biol Chem</u> 267(24):17082-17088 (1992)	
	EU	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> 39:1159-1165 (1989)	
	EV	MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am J Pathol</u> 144(5):1082-1088 (1994)	
	EW	NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim Biophys Acta</u> 104:480-486 (1965)	
	EX	PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem Biophys Res Comm</u> 146:307-313 (1987)	
	EY	PRIEELS et al, "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994)	
	EZ	QUON et al, "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> 352:239-241 (1991)	
	FA	ROGERS et al, "Complement activation by β -amyloid in Alzheimer Disease," <u>Proc Natl Acad Sci USA</u> , 89:1-5 (1992)	
	FB	ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Ann of NY Acad Sci</u> , 695:198-202 (1993)	
ESB	FC	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976)	

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTG

(use as many sheets as necessary)

Sheet

1

Q

2

Complete if Known

Application Number	09/441,140
--------------------	------------

Filing Date	November 16, 1999
--------------------	-------------------

First Named Inventor	Beka SOLOMON
----------------------	--------------

Group Art Unit	1642 1647
----------------	----------------------

Examiner Name	E. Banzai NICHOLS
---------------	------------------------------

Attorney Docket Number	SOLOMON=1R
------------------------	------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

7/30/2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

